A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB

ClinicalTrials.gov ID: NCT03530852

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03530852. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition

Study identification

NCT ID: NCT03530852
Recruitment status: Recruiting
Study type: Interventional
Phase: Not applicable
Lead sponsor: Boston Children's Hospital; Other
Enrollment: 32 participants

Conditions and interventions

Conditions

Interventions

Relizorb Device

Device

Eligibility (public fields only)

Age range: 2 Years to 18 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 21, 2018 (Actual)
Primary completion: Jun 30, 2027 (Estimated)
Completion: Sep 30, 2028 (Estimated)
Last update posted: Aug 3, 2026

2018 – 2028

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Children's Hospital Los Angeles	Los Angeles	California	90027	Recruiting
Boston Children's Hospital	Boston	Massachusetts	02115	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03530852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 3, 2026 · Synced Nov 14, 2026